Page 21 - Lupin

Lupin appoints K B S Anand, Punita Kumar Sinha as independent directors

Drug firm Lupin on Wednesday announced the appointment of K B S Anand and Punita Kumar-Sinha as independent directors. Anand most recently served as managing director and chief executive officer at Asian Paints. He currently serves as an independent director on the boards of Marico, Tata Chemicals and Borosil, Lupin said in a filing to BSE. Punita Kumar-Sinha brings significant governance and investment experience across India and North America. She founded Pacific Paradigm Advisors, an independent investment advisory and management firm, and was formerly a senior managing director at Blackstone, it added. She serves as an independent director for several companies, including Infosys, JSW Steel, Blackstone Embassy REIT and Rallis, Lupin said. "We are delighted to welcome Mr K B S Anand and Dr Punita Kumar-Sinha to our board. With their long and illustrious careers, they bring decades of experience in key areas such as innovation, strategy, capital markets and financial expertise

Lupin pharma launches generic asthma treatment drug in US market

Drug firm Lupin on Tuesday said it has launched generic Zileuton extended-release tablets - used for the treatment of asthma - in the US market. The product is a generic version of Chiesi USA Inc's Zyflo CR extended-release tablets in the same strength, it added. The company has launched Zileuton extended-release tablets in the strength of 600 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a BSE filing. According to IQVIA MAT June 2020 data, Zileuton extended-release tablets had an annual sales of approximately USD 40 million in the US, Lupinsaid. The tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older, it added. Shares of Lupin Ltd closed at Rs957.95per scrip on the BSE, up 0.01 per cent from its previous close.

Lupin, Sun Pharma recalling products in the US market, says USFDA

Leading drug makers Lupin and Sun Pharma are recalling different products in the US, according to the US Food and Drug Administration (USFDA).

Weak US sales drags Lupin's Q1 show, revival hinges on key launches

The company reported a sharp 21 per cent decline in revenues in the US, much higher than its peers

Lupin Q1 net profit drops 65% to Rs 107 crore slammed by Covid-19

Consolidated total revenue from operations stood at Rs 3,527.9 crore for the quarter under consideration. It was Rs 3,877.7 crore for the same period a year ago

Lupin plunges 6% as June quarter profit tanks 60% YoY to Rs 107 crore

EBITDA tood at Rs 531.4 cror for the quarter under review, down 34.7 per cent, from Rs 813.4 crore of Q1FY20, and by 27.6 per from Rs 733.9 crore logged in Q4FY20

Lupin alliance partner Concord gets USFDA nod for generic medicine

Concord has received approval from the US Food and Drug Administration (USFDA) to market the drug to prevent organ transplant rejection

Alkem Lab jumps 4.5% as it launches Favipiravir drug to treat Covid-19

Alkem Laboratories has launched Favipiravir under the brand name 'Alfluenza' in India for the management of mild to moderate cases of Covid-19

Lupin launches Covid-19 drug Favipiravir in India at Rs 49 per tablet

Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use of its product

Weekly trading ideas by Religare Broking: Buy Bharti Airtel, Titan Company

TITAN, after the breakout from a consolidation range, is gradually inching higher while holding strongly above the support zone of the long term moving average( 200 EMA) on the daily chart

Lupin gets US FDA approval to market generic diabetes drug in the US

The Mumbai-based company has received a tentative approval from the USFDA for its Empagliflozin tablets

Lupin shuts manufacturing plant after 17 staff test Covid-19 positive

The firm has some 11 manufacturing plants at the Ankleshwar site in Gujarat state, which is spread out over 40 acres and has 984 employees, according to the company website.

Lupin recalls diabetes treatment drug Metformin Hydrochloride in US

Drug major Lupin Ltd on Wednesday said it is voluntarily recalling its diabetes treatment drug Metformin Hydrochloride extended-release tablets in the US market

India's coronavirus drug market set for price war as firms ready launches

Sources say Cipla-BDR's favipiravir will be at least 30 per cent cheaper than Glenmark's price of Rs 103 per tablet. Cipla did not confirm.

Nifty outlook & stock calls by Anand Rathi: Buy Lupin, Mahanagar Gas

Lupin's stock is making a higher top and higher bottom pattern on the daily chart

US FDA grants orphan drug status to mexiletine hydrochloride: Lupin

The Mumbai-based company's drug NaMuscula (mexiletine hydrochloride) is the first and only licensed product to treat myotonia in adults with non-dystrophic myotonic (NDM) disorders

New launches, cost-control efforts, margin improvement crucial for Lupin

Resolution of compliance issues at Goa, Indore plants are other triggers

Lupin steps up production of key drugs in potential use for Covid-19

Expects US approval for Albuterol soon

Lupin reports 25% fall in pre-tax profit at Rs 412 cr in Q4 on low sales

On a sequential basis, however, the company fared better, both in terms of sales and profits. The stock ended day's trade at Rs 869.8, down 1.3 per cent.

Lupin Q4 net profit up 35% to Rs 390 cr on robust sales, lower tax expenses

In the current times, Lupin has been able to ensure business continuity while safeguarding the health and safety of its employees